Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
Rhea-AI Summary
Assembly Biosciences (Nasdaq: ASMB) announced that chief medical officer Anuj Gaggar, MD, PhD, will present at the BofA Securities 2026 Global Health Care Conference at 4:35 p.m. PT on May 13, 2026. A live webcast and replay will be available via the company’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – ASMB
In the May 11 session, ASMB gained 2.25%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 09 | Clinical data presentations | Positive | +1.7% | Positive Phase 1b HSV data for ABI-5366 and ABI-1179 highlighted at ESCMID. |
| Mar 19 | Earnings and pipeline | Positive | +3.5% | Year-end 2025 results with collaboration revenue, strong cash and pipeline progress. |
| Dec 22 | Licensing agreement | Positive | +2.6% | Gilead exercised option to license HSV helicase-primase programs with milestones. |
| Dec 08 | Interim trial results | Positive | +0.8% | Interim Phase 1b herpes data showing large reductions in shedding and lesions. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company news, including clinical and partnership updates, has generally been followed by modest positive price reactions.
Over the past several months, Assembly Biosciences has reported a series of positive developments. On Dec 8, 2025, the company announced strong interim Phase 1b data for HSV candidates ABI-1179 and ABI-5366, followed by Gilead exercising its option on these programs on Dec 22, 2025. Year-end 2025 results on Mar 19, 2026 highlighted collaboration revenue and a manageable net loss. Additional positive Phase 1b data presentations were flagged on Apr 9, 2026. Today’s conference participation fits into an ongoing pattern of active clinical and partnering communication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, chief medical officer, will present during the Bank of America Securities 2026 Global Health Care Conference at 4:35 p.m. Pacific Time on May 13, 2026.
A live webcast will be available on the Events and Presentations section of Assembly Bio’s website, and a replay will be accessible following the event. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/events-presentations.
About Assembly Biosciences
Assembly Biosciences is a biotechnology company dedicated to the development of innovative small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections. For more information, visit assemblybio.com.
Forward-Looking Statements
The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to realize the potential benefits of its collaboration with Gilead Sciences, Inc. (Gilead), including all financial aspects of the collaboration and equity investments; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration with Gilead, in the currently anticipated timeframes or at all; safety and efficacy data from clinical or nonclinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data may not differentiate Assembly Bio’s product candidates from other companies’ candidates; Assembly Bio’s ability to maintain financial resources necessary to continue its research activities, clinical studies and other business operations; potential effects of changes in government regulation; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Investors:
Patrick Till
Meru Advisors
(484) 788-8560
investor_relations@assemblybio.com
Media:
Sam Brown Healthcare Communications
Jaime Strachota
(703) 819-7647
ASMBMedia@sambrown.com
